Clinical trial NCT05108623 - References

Tumor, Solid — A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid Tumors

Citation(s)

•   Hadfield MJ, Safran H, Purbhoo MA, Grossman JE, Buell JS, Carneiro BA
  Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT). Oncogene. 2024 Mar;43(10):758-762. doi: 10.1038/s41388-024-02948-y. Epub 2024 Jan 29.

A Phase 1, Open-Label Study of the Safety, Tolerability and Preliminary Clinical Activity of Allogeneic Invariant Natural Killer T (iNKT) Cells (agenT-797) as a Single Agent and in Combination With Approved Immune Checkpoint Inhibitors in Patients With Relapsed/ Refractory Solid Tumors

Details for clinical trial NCT05108623